细胞因子诱导的杀伤细胞联合白细胞介素2治疗恶性胸腔积液

目的 观察应用细胞因子诱导的杀伤（CIK）细胞联合白细胞介素2（IL-2）治疗恶性胸腔积液的疗效.方法 收集2009年7月至2013年7月于本院肿瘤科就诊的恶性胸腔积液患者50例,随机数字表法分为治疗组（n=24）和对照组（n=26）.胸腔积液引流净后,治疗组胸腔灌注CIK细胞联合IL-2,连续3d;对照组灌注IL-2联合顺铂,隔日1次,连续3次.治疗4周后评价疗效和不良反应.结果 治疗组有效率87.50％（21/24）,完全缓解率54.17％（13/24）;对照组有效率57.69％（15/26）,完全缓解率42.31％（11/26）.与对照组比较,治疗组的完全缓解率、有效率均增加（均P＜0.05）.不良反应比较显示,治疗组发热的发生率较高,而对照组胸痛、胃肠道反应、骨髓抑制的发生率较高（均P＜ 0.05）.与治疗前比较,治疗后两组患者的Karnofsky评分均增加（均P＜0.05）.结论 CIK细胞联合IL-2胸腔灌注治疗恶性胸腔积液不良反应小,疗效确切.

Treatment of malignant pleural effusion by cytokine-induced killer cells combined with interleukin-2

Objective To observe the efficacy of malignant pleural effusion treated by cytokine-induced killer （CIK） cells combined with interleukin-2 （IL-2）.Methods Fifty patients with malignant pleural effusion in oncology clinic of our hospital from July 2009 to July 2013 were recruited and divided into treatment group （n=24） and control group （n=26） by random number table.After pleura1 puncture and drainage,the treatment group were treated with interpleural injection of CIK cells and IL-2 for 3 days continuously,while the control group were treated with interpleural injection of IL-2 and cisplatin for 3 times in every other day.The efficacy and adverse effects were evaluated at 4 weeks after treatment.Results The effective rate and complete remission rate in treatment group were 87.50％ （21/24） and 54.17％ （13/24）,while those in control group were 57.69％ （15/26） and 42.31％ （11/26）.Compared with control group,the complete remission rate and the effective rate increased in treatment group （both P ＜ 0.05）.Comparison of adverse effects showed a higher incidence of fever in treatment group,and higher incidence of chest pain,gastrointestinal reactions and myelosuppression in the control group （all P＜0.05）.As compared with pretreatment,the Karnofsky scores of patients in both groups increased after treatment （both P＜0.05）.Conclusion The therapy of malignant pleural effusion treated by interpleural injection of CIK cells combined with IL-2 shows a reliable efficacy and less adverse effects.